J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz Post author:Sam Post published:January 25, 2018 Post category:BioPharma Now insiders say J&J has decided it is no longer interested. Source: BioSpace You Might Also Like FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration January 28, 2018 Ardelyx Shares Soared After Positive Phase III Results for Tenapanor October 11, 2017 11 Most Innovative Life Science Companies in the World February 20, 2018
FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration January 28, 2018
